(PDF) Correction 2: Everolimus (EVE) and Exemestane (EXE)

Correction 2: Everolimus (EVE) and Exemestane (EXE) in Patients With Advanced Breast Cancer Aged &#X2265; 65 Years: New Lessons for Clinical Practice From the EVA Study

Oncotarget - United States

doi 10.18632/oncotarget.26431

Full Text

Open PDF

Abstract

Available in full text

Date

November 30, 2018

Authors

Maria Rosaria Valerio

Maria Concetta Cursano

Publisher

Impact Journals, LLC

Amanote Research

Correction 2: Everolimus (EVE) and Exemestane (EXE) in Patients With Advanced Breast Cancer Aged &#X2265; 65 Years: New Lessons for Clinical Practice From the EVA Study

Oncotarget - United States

doi 10.18632/oncotarget.26431

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Correction: Everolimus (EVE) and Exemestane (EXE) in Patients With Advanced Breast Cancer Aged &#X2265; 65 Years: New Lessons for Clinical Practice From the EVA Study

Costs of HER 2 Negative, Hormonal Receptor Positive, Metastatic Breast Cancer (MBC-HR+) Treated With Everolimus (EVE) + Exemestane (EXE) in the Brazilian Private System (BPS): A Real World (RW) and Published Literature Analysis

Imatinib and Everolimus in Patients With Progressing Advanced Chordoma: A Phase 2 Clinical Study

Exemestane for Locally Advanced Breast Cancer: A Case Report

Clinical and Audiologic Characteristics of Tinnitus in Subjects Aged <65 and ≥65 Years

Correction To: Neutropenia Management With Palbociclib in Japanese Patients With Advanced Breast Cancer

Hormone Treatment Without Surgery for Patients Aged 75 Years or Older With Operable Breast Cancer

Characteristics of the Gastric Cancer in the Aged(over 65 Years Old).

Clinical and Economic Analysis of Effectiveness of Everolimus in the Treatment of HR+, HER2- Advanced Breast Cancer in Russia